Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | ACP3 | P15309 | 2/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.48 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.48 |
| ▸ | HTR1A | P08908 | 1/20 | 0.48 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.48 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.48 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.48 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.48 |
| ▸ | DRD1 | P21728 | 1/20 | 0.48 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.48 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.48 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.48 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.48 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.48 |
| ▸ | DRD3 | P35462 | 1/20 | 0.48 |
| ▸ | CASR | P41180 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8433113 | 1.00 | SIGMAR1 (0.57) | SIGMAR1GAAL3MBTL1ACP3CYP3A4 | |
| SCHEMBL8433689 | 1.00 | SIGMAR1 (0.57) | SIGMAR1GAAL3MBTL1ACP3CYP3A4 | |
| Benzene SCHEMBL10772069 | 1.00 | SIGMAR1 (0.57) | SIGMAR1GAAL3MBTL1ACP3CYP3A4 | |
| SCHEMBL5399360 | 0.97 | SIGMAR1 (0.55) | SIGMAR1GAAL3MBTL1ACP3CYP3A4 | |
| SCHEMBL283979 | 0.89 | SIGMAR1 (0.61) | SIGMAR1GAAL3MBTL1ACP3CYP3A4 | |
| SCHEMBL30763462 | 0.89 | SIGMAR1 (0.61) | SIGMAR1GAAL3MBTL1ACP3CYP3A4 | |
| SCHEMBL3749295 | 0.89 | SIGMAR1 (0.61) | SIGMAR1GAAL3MBTL1ACP3CYP3A4 | |
| SCHEMBL8437895 | 0.89 | SIGMAR1 (0.61) | SIGMAR1GAAL3MBTL1ACP3CYP3A4 | |
| SCHEMBL1200137 | 0.89 | SIGMAR1 (0.61) | SIGMAR1GAAL3MBTL1ACP3CYP3A4 | |
| Hydrochloric Acid SCHEMBL607712 | 0.86 | SIGMAR1 (0.59) | SIGMAR1GAAL3MBTL1ACP3CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 122 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109336887-B | Benzimidazole chiral heterocyclic compound and preparation method and application thereof | 中山大学 | 2021-12-17 | — | — | CN | claimed |
| US-12036209-B2 | Compounds and methods for the targeted degradation of Interleukin-1 receptor-associated kinase 4 polypeptides | ARVINAS OPERATIONS, INC. (US) | 2024-07-16 | — | — | US | disclosed |
| CN-117327050-A | Bimetal synergistic promotion system and application thereof in asymmetric synthesis of (S, S) -TBAJ-587 | 上海交通大学 | 2024-01-02 | — | — | CN | disclosed |
| US-11857519-B2 | Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide | ARVINAS OPERATIONS, INC. (US) | 2024-01-02 | — | — | US | disclosed |
| US-11857519-B2 | Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide | ARVINAS OPERATIONS, INC. (US) | 2024-01-02 | — | — | US | disclosed |
| US-11833208-B2 | PLK1 selective degradation inducing compound | UPPTHERA, INC. (KR) | 2023-12-05 | — | — | US | disclosed |
| US-11707452-B2 | Modulators of alpha-synuclein proteolysis and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2023-07-25 | — | — | US | disclosed |
| US-20230159446-A1 | Methods and Compositions for Targeting Tregs using CCR8 Inhibitors | NANJING IMMUNOPHAGE BIOMEDICAL CO., LTD. (CN) | 2023-05-25 | — | — | US | disclosed |
| US-20230041518-A1 | QUINOLINE DERIVATIVES | GILEAD SCIENCES, INC. | 2023-02-09 | — | — | US | disclosed |
| US-20230033360-A1 | COMPOUNDS AS CD73 INHIBITORS | BIOARDIS LLC | 2023-02-02 | — | — | US | disclosed |
| US-20070105832-A1 | Substituted azetidinones | Cadrenal Therapeutics, Inc. | 2007-05-10 | — | — | US | disclosed |
| US-7179940-B2 | (Aryl)(amino) borane compounds, method for preparing same | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2007-02-20 | — | — | US | disclosed |
| US-7179940-B2 | (Aryl)(amino) borane compounds, method for preparing same | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2007-02-20 | — | — | US | disclosed |
| US-20070037803-A1 | 2-Amino-imidazole derivatives; modulate the expression and/or function of proteins involved in inflammation, immune response regulation and cell proliferation | AMGEN SF, LLC (US) | 2007-02-15 | — | — | US | disclosed |
| US-20070032433-A1 | Novel peptides as NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION CORVAS INTERNATIONAL, LTD. | 2007-02-08 | — | — | US | disclosed |
| EP-1458729-B1 | (ARYL) (AMINO) BORANE COMPOUNDS, METHOD FOR PREPARING SAME | CENTRE NAT RECH SCIENT (FR) | 2006-03-08 | — | — | EP | disclosed |
| US-20040097560-A1 | N-alkyl-4-methyleneamino-3-hydroxy-2-pyridones | THE PROCTER & GAMBLE COMPANY | 2004-05-20 | — | — | US | disclosed |
| US-5977409-A | Method of using α-substituted benzylamine chiral auxiliary synthetic reagents | UNIVERSITY OF TOLEDO (US) | 1999-11-02 | — | — | US | disclosed |
| US-4958029-A | Process for the production of isoindoline derivatives, novel intermediates and process for their production | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1990-09-18 | — | — | US | disclosed |
| EP-0275064-A2 | Process for the production of isoindoline derivatives, novel intermediates and process for their production | Banyu Pharmaceutical Co., Ltd. (JP) | 1988-07-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070105832-A1 | Substituted azetidinones | F2R, CPA3, CFD | SIGMAR1 4607/4885GAA 507/4885L3MBTL1 4390/4885 |
| US-20230159446-A1 | Methods and Compositions for Targeting Tregs using CCR8 Inhibitors | CCR8, CCR1, CCR3 | SIGMAR1 4425/4885GAA 3646/4885L3MBTL1 4338/4885 |
| US-20230033360-A1 | COMPOUNDS AS CD73 INHIBITORS | ENTPD5, ENTPD1, NT5E | SIGMAR1 4818/4885GAA 195/4885L3MBTL1 3880/4885 |
| US-20040097560-A1 | N-alkyl-4-methyleneamino-3-hydroxy-2-pyridones | IL17A, CYP51A1, CD4 | SIGMAR1 1452/4885GAA 1885/4885L3MBTL1 2289/4885 |
| US-20070037803-A1 | 2-Amino-imidazole derivatives; modulate the expression and/or function of proteins involved in inflammation, immune response regulation and cell proliferation | IDO2, IRF2BP2, IRF3 | SIGMAR1 4477/4885GAA 4796/4885L3MBTL1 4114/4885 |
| US-12036209-B2 | Compounds and methods for the targeted degradation of Interleukin-1 receptor-associated kinase 4 polypeptides | IRAK1, IRAK4, IRAK2 | SIGMAR1 2905/4885GAA 1274/4885L3MBTL1 1477/4885 |
| US-20230041518-A1 | QUINOLINE DERIVATIVES | CFTR, NQO1, IRF3 | SIGMAR1 709/4885GAA 252/4885L3MBTL1 4861/4885 |
| US-11707452-B2 | Modulators of alpha-synuclein proteolysis and associated methods of use | UCHL1, ADRM1, CRBN | SIGMAR1 2774/4885GAA 265/4885L3MBTL1 479/4885 |
| US-11857519-B2 | Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide | CRBN, MDM2, VHL | SIGMAR1 4536/4885GAA 486/4885L3MBTL1 401/4885 |
| US-20070032433-A1 | Novel peptides as NS3-serine protease inhibitors of hepatitis C virus | HPN, TMPRSS15, VIP | SIGMAR1 3270/4885GAA 725/4885L3MBTL1 1897/4885 |
| US-11833208-B2 | PLK1 selective degradation inducing compound | PLK1, BUB1B, BUB1 | SIGMAR1 4807/4885GAA 2410/4885L3MBTL1 719/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.